Total Payments
$470,193
2024 Payments
$58,249
Companies
21
Transactions
301
Medicare Patients
2,623
Medicare Billing
$383,373
Payment Breakdown by Category
Consulting$343,411 (73.0%)
Other$60,100 (12.8%)
Travel$54,038 (11.5%)
Food & Beverage$7,148 (1.5%)
Research$5,495 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $343,411 | 101 | 73.0% |
| Travel and Lodging | $54,038 | 69 | 11.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $47,735 | 13 | 10.2% |
| Honoraria | $12,365 | 5 | 2.6% |
| Food and Beverage | $7,148 | 108 | 1.5% |
| Unspecified | $5,495 | 5 | 1.2% |
Payments by Type
General
$464,698
296 transactions
Research
$5,495
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | $156,396 | 97 | $0 (2024) |
| Amgen Inc. | $103,975 | 31 | $0 (2021) |
| Eli Lilly and Company | $41,083 | 35 | $0 (2024) |
| PFIZER INC. | $36,555 | 16 | $0 (2023) |
| Janssen Research & Development, LLC | $31,509 | 17 | $0 (2024) |
| Janssen Global Services, LLC | $26,329 | 32 | $0 (2022) |
| Astellas Pharma US Inc | $24,049 | 11 | $0 (2021) |
| Astellas Pharma Global Development | $12,315 | 10 | $0 (2019) |
| Hexal AG | $8,392 | 7 | $0 (2018) |
| Janssen Biotech, Inc. | $5,972 | 3 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $58,249 | 33 | Bayer Healthcare Pharmaceuticals Inc. ($35,180) |
| 2023 | $31,027 | 17 | Eli Lilly and Company ($12,465) |
| 2022 | $31,485 | 14 | Bayer HealthCare Pharmaceuticals Inc. ($20,825) |
| 2021 | $31,236 | 15 | PFIZER INC. ($13,565) |
| 2020 | $45,467 | 21 | Astellas Pharma US Inc ($19,358) |
| 2019 | $61,119 | 55 | Bayer HealthCare Pharmaceuticals Inc. ($24,294) |
| 2018 | $88,879 | 61 | Bayer HealthCare Pharmaceuticals Inc. ($39,751) |
| 2017 | $122,731 | 85 | Amgen Inc. ($69,104) |
All Payment Transactions
301 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/18/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Consulting Fee | Cash or cash equivalent | $721.00 | General |
| Category: Oncology | ||||||
| 10/10/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| 09/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $7,700.00 | General |
| 09/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $3,500.00 | General |
| 09/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $137.05 | General |
| 09/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $101.67 | General |
| 08/20/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Travel and Lodging | In-kind items and services | $3,182.60 | General |
| Category: Oncology | ||||||
| 08/20/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Travel and Lodging | In-kind items and services | $247.44 | General |
| Category: Oncology | ||||||
| 08/20/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Travel and Lodging | In-kind items and services | $209.00 | General |
| Category: Oncology | ||||||
| 08/20/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $49.50 | General |
| Category: Oncology | ||||||
| 08/20/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $16.50 | General |
| Category: Oncology | ||||||
| 08/20/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $16.50 | General |
| Category: Oncology | ||||||
| 08/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Travel and Lodging | In-kind items and services | $209.00 | General |
| Category: Oncology | ||||||
| 08/01/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Consulting Fee | Cash or cash equivalent | $1,442.00 | General |
| Category: Oncology | ||||||
| 07/26/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Consulting Fee | Cash or cash equivalent | $7,210.00 | General |
| Category: Oncology | ||||||
| 07/26/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Travel and Lodging | In-kind items and services | $492.27 | General |
| Category: Oncology | ||||||
| 07/26/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Travel and Lodging | In-kind items and services | $143.10 | General |
| Category: Oncology | ||||||
| 07/26/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Travel and Lodging | In-kind items and services | $130.05 | General |
| Category: Oncology | ||||||
| 07/26/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Travel and Lodging | In-kind items and services | $115.69 | General |
| Category: Oncology | ||||||
| 07/26/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $97.01 | General |
| Category: Oncology | ||||||
| 07/25/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Travel and Lodging | In-kind items and services | $274.19 | General |
| Category: Oncology | ||||||
| 07/25/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Travel and Lodging | In-kind items and services | $260.10 | General |
| Category: Oncology | ||||||
| 06/11/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| Category: Oncology | ||||||
| 06/01/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $239.68 | General |
| 06/01/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $181.89 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2, Open-label, Single-arm, Efficacy and Safety Study of Enzalutamide (MDV3100) in Patients With Hormone-naive Prostate Cancer | Astellas Pharma Global Development | $1,013 | 1 |
| A phase 2, open-label, single-arm, efficacy and safety study of MDV3100 in patients with hormone-naive prostate cancer | Astellas Pharma Global Development | $631.00 | 1 |
| A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide Who Are at Potential Increased Risk of Seizure | Astellas Pharma Global Development | $266.00 | 1 |
| A STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CANCER | Eli Lilly and Company | $54.75 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 566 | 962 | $535,223 | $96,702 |
| 2022 | 6 | 659 | 1,120 | $578,937 | $111,989 |
| 2021 | 5 | 664 | 1,047 | $453,005 | $100,262 |
| 2020 | 7 | 734 | 1,062 | $377,541 | $74,420 |
Total Patients
2,623
Total Services
4,191
Medicare Billing
$383,373
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 326 | 668 | $415,196 | $76,597 | 18.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 200 | 248 | $101,473 | $16,990 | 16.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 40 | 46 | $18,554 | $3,115 | 16.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 284 | 588 | $359,700 | $69,883 | 19.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 271 | 381 | $152,853 | $28,587 | 18.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 58 | 71 | $28,259 | $5,301 | 18.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 21 | 55 | $22,394 | $4,842 | 21.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 14 | 14 | $11,078 | $2,375 | 21.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 11 | 11 | $4,653 | $1,001 | 21.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 255 | 510 | $273,386 | $60,671 | 22.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 263 | 367 | $129,182 | $28,705 | 22.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 90 | 113 | $38,111 | $8,742 | 22.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 40 | 41 | $8,982 | $1,983 | 22.1% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 16 | 16 | $3,344 | $160.54 | 4.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 215 | 403 | $199,360 | $37,937 | 19.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 232 | 326 | $109,912 | $19,756 | 18.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 72 | 80 | $17,310 | $5,492 | 31.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 102 | 109 | $25,496 | $4,001 | 15.7% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 75 | 85 | $10,382 | $3,639 | 35.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 12 | 33 | $13,755 | $3,023 | 22.0% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Facility | 2020 | 26 | 26 | $1,326 | $573.03 | 43.2% |
About Matthew Smith, MD PHD
Matthew Smith, MD PHD is a Medical Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/08/2005. The National Provider Identifier (NPI) number assigned to this provider is 1679554588.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Matthew Smith, MD PHD has received a total of $470,193 in payments from pharmaceutical and medical device companies, with $58,249 received in 2024. These payments were reported across 301 transactions from 21 companies. The most common payment nature is "Consulting Fee" ($343,411).
As a Medicare-enrolled provider, Smith has provided services to 2,623 Medicare beneficiaries, totaling 4,191 services with total Medicare billing of $383,373. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Internal Medicine
- Location Boston, MA
- Active Since 11/08/2005
- Last Updated 01/26/2026
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1679554588
Products in Payments
- XGEVA (Biological) $82,619
- Nubeqa (Drug) $41,202
- XTANDI (Drug) $30,675
- TALZENNA (Drug) $20,735
- Erleada (Drug) $15,589
- Non-Covered $7,577
- ORGOVYX (Drug) $6,875
- Xtandi (Drug) $5,654
- Xofigo (Drug) $5,280
- Non-Covered (Drug) $4,900
- JEVTANA (Drug) $2,943
- Prolia (Biological) $2,750
- ZYTIGA (Drug) $2,518
- LYNPARZA (Drug) $2,398
- ERLEADA (Drug) $2,060
- Enzalutamide (Drug) $1,910
- PROVENGE (Drug) $1,400
- VERZENIO (Drug) $468.51
- NO PRODUCT DISCUSSED (Drug) $429.95
- LINZESS (Drug) $87.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Boston
Dr. George Demetri, Md, MD
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Pasi Antero Janne, Md Phd, MD PHD
Medical Oncology — Payments: $1.1M
Medical Oncology $1.1M
Dr. Praful Ravi, Mb Bchir, MB BCHIR
Medical Oncology — Payments: $921,658
Medical Oncology $921,658
Dr. Alicia Morgans, Md, MD
Medical Oncology — Payments: $755,277
Medical Oncology $755,277
Dr. Erica Mayer, Md Mph, MD MPH
Medical Oncology — Payments: $665,160
Medical Oncology $665,160
Dr. Joaquin Bellmunt Molins, M.d, M.D
Medical Oncology — Payments: $610,701
Medical Oncology $610,701